LifeCycle Pharma, an emerging specialty pharmaceutical company, has launched its first product Fenoglide(TM) for the treatment of hyperlipidemia and hypertriglyceridemia in US

LifeCycle Pharma  has launched the cholesterol lowering Fenoglide(TM) (formerly LCP-FenoChol) for the treatment of hyperlipidemia and hypertriglyceridemia named as  Fenoglide(TM). The U.S. Food and Drug Administration (FDA) has given its approval and will be marketed by its partner Sciele Pharma Inc.

Fenoglide will be the lowest dose of fenofibrate available i.e  in 40 mg and 120 mg strength tablets. Fenoglide utilizes LCP's unique MeltDose(R) technology, a clinically validated reformulation technology, designed to provide enhanced absorption and greater bioavailability of the drug.